Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.
Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.
Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.
Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) reported first quarter 2024 financial results with a total revenue of $38 million, down 53% YoY. The company announced initiatives to reduce operating expenses by $200 million by mid-2025 to achieve Adjusted EBITDA breakeven by end of 2026. Despite a loss from operations of $(178) million, Ginkgo maintains a cash balance of $840 million. The company aims to simplify operations, expand partnerships, and introduce new offerings to drive revenue growth.
GreenLab partners with Ginkgo Bioworks to scale up production of brazzein, a novel sweetener found in the fruit of the West African Oubli plant. This partnership aims to revolutionize the sweetener industry by leveraging GreenLab's technology to grow proteins in corn kernels and Ginkgo's capabilities to optimize production. By using Plant Trait Services, Protein Services, and Deployment Capabilities, GreenLab intends to be a leading supplier of brazzein to food and beverage companies, reducing market and technical risks.
Ginkgo Bioworks (NYSE: DNA) will be presenting at the ASGCT Annual Meeting, showcasing advancements in genetic medicines. The company will present posters on CAR signaling optimization and gene therapy design, highlighting their innovative platform. Ginkgo has grown its genetic medicine services and acquired Patch Biosciences to expand capabilities. The presentations demonstrate Ginkgo's commitment to driving innovation in genetic medicine development.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) will host a presentation and Q&A session to review business performance for the first quarter of 2024 on May 9, 2024. The event will begin at 5:30 p.m. ET and can be accessed via the company's investor relations website. Questions can be submitted in advance via social media or email.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
